The effect of telmisartan and ramipril on early morning blood pressure surge: A pooled analysis of two randomized clinical trials

Blood Pressure Monitoring

Volumn 12, Issue 3, 2007, Pages 141-147

  Gosse, Philippe ^a   Neutel, Joel M ^b   Schumacher, Helmut ^d   Lacourcière, Yves ^e   Williams, Bryn ^f   Davidai, Giora ^c  

^a HÔPITAL SAINT ANDRÉ   (France)

^b Orange County Research Center   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e Quebec Hospital   (Canada)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Ambulatory blood pressure monitoring; Early morning blood pressure surge; Hypertension; Ramipril; Telmisartan

Indexed keywords

RAMIPRIL; TELMISARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; NIGHT; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SLEEP PATTERN; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RAMIPRIL; TIME FACTORS;

EID: 34248572826     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBP.0b013e3280b10bbd     Document Type: Article

References (33)

1. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978; i:795-797.
2. Narkiewicz K, Winnicki M, Schroeder K, Phillips BG, Kato M, Cwalina E, et al. Relationship between muscle sympathetic nerve activity and diurnal blood pressure profile. Hypertension 2002; 39:168-172.
3. Etsuda H, Takase B, Uehata A, Kusano H, Hamabe A, Kuhara R, et al. Morning attenuation of endothelium-dependent, flow-mediated dilation in healthy young men: possible connection to morning peak of cardiac events? Clin Cardiol 1999; 22:417-421.
4. Gordon RD, Wolfe LK, Island DP, Liddle GW. A diurnal rhythm in plasma renin activity in man. J Clin Invest 1966; 45:1587-1592.
5. Elliott WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens 2001; 14:291S-295S.
6. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001; 6:63-72.
7. Polonia J, Amado P, Barbosa L, Nazare J, Silva JA, Bertoquini S, et al. Morning rise, morning surge and daytime variability of blood pressure and cardiovascular target organ damage. A cross-sectional study in 743 subjects. Rev Port Cardiol 2005; 24:65-78.
8. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657-671.
9. Kleinpeter G, Schatzer R, Bock F. Is blood pressure really a trigger for the circadian rhythm of subarachnoid hemorrhage? Stroke 1995; 26:1805-1810.
10. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107:1401-1406.
11. Gosse P, Lasserre R, Minifie C, Lemetayer P, Clementy J. Blood pressure surge on rising. J Hypertens 2004; 22:1113-1118.
12. Mancia G, Parati G. Importance of smooth and sustained blood pressure control in preventing cardiovascular morbidity and mortality. Blood Press Suppl 2001; 3:26-32.
13. Elliott HL, Meredith PA. Trough:peak ratio: clinically useful or practically irrelevant? J Hypertens 1995; 13:279-283.
14. McCarron D. 24-h blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: magnitude and duration of antihypertensive effects. Ramipril Multicenter Study Group. Clin Cardiol 1991; 14:737-742.
15. Neutel JM. Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker - telmisartan. Blood Press 2001; 10 (Suppl 1):27-32.
16. Williams B, Gosse P, Lowe L, Harper R, on behalf of the PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006; 24:193-200.
17. Lacourcière Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19:104-112.
18. Hansson L, Hedner T, Dahlòf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Blood Press 1992; 1:113-119.
19. Chau NP, Mallion JM, de Gaudemaris R, Ruche E, Siche JP, Pelen O, et al. Twenty-four-hour ambulatory blood pressure in shift workers. Circulation 1989; 80:341-347.
20. Eguchi K, Kario K, Shimada K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am J Cardiol 2003; 92:621-624.
21. Eguchi K, Kario K, Hoshide Y, Hoshide S, Ishikawa J, Morinari M, et al. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. Am J Hypertens 2004; 17:112-117.
22. Radauceanu A, Boivin JM, Bernaud C, Fay R, Zannad F. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol. Fundam Clin Pharmacol 2004; 18:483-491.
23. Kumagai Y. Strategies against high blood pressure in the early morning. Clin Exp Hypertens 2004; 26:107-118.
24. White WB. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens Suppl 2003; 21 (Suppl 6):S9-S15.
25. Lamarre-Cliche M, de Champlain J, Lacourciere Y, Poirier L, Karas M, Larochelle P. Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives. Am J Hypertens 2005; 18:56-64.
26. White WB, Lacourcière Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17:347-353.
27. Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998; 3:295-302.
28. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38:852-857.
29. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
30. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38:E28-E32.
31. Fujii J, Seki A. Compliance and compliance-improving strategies in hypertension: the Japanese experience. J Hypertens Suppl 1985; 3:S19-S22.
32. Mengden T, Binswanger B, Spuhler T, Weisser B, Vetter W. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens 1993; 11:1403-1411.
33. Teo K, Yusuf S, Anderson C, Mookadam F, Ramos B, Hilbrich L, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148:52-61.